CoChat

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Open access

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.

Abstract

Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

Overview

CoChat Summary

TL;DR

An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.

Key findings

  • For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
  • For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
  • TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
  • In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).

Methods

  • Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
  • Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
  • Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.

Limitations

  • The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
  • The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
  • Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2337/dci19-0028

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations

37 more claims · 16 with their cited sources checked

Create a free account to see all 67 claims and to verify the 4 references still open.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 13

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

16 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 106 references

Cited by

Items 1,701–1,800 of 3,959

Metadata

Authors
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
Affiliations
  • University of Ljubljana (SI)
  • Kinderkrankenhaus auf der Bult (DE)
  • Park Nicollet Health Services (US)
  • King's College London (GB)
  • Jaeb Center for Health Research (US)
  • Vita-Salute San Raffaele University (IT)
  • Stanford Medicine (US)
  • American Diabetes Association (US)
  • Close Concerns (United States) (US)
  • University of Padua (IT)
  • Harvard University (US)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • The University of Sydney (AU)
  • Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
  • University of Colorado Denver (US)
  • Grunberger Diabetes Institute (US)
  • University of Sheffield (GB)
  • Science Consulting in Diabetes, Neuss, Germany
  • University of Washington (US)
  • University of Cambridge (GB)
  • Shanghai Jiao Tong University (CN)
  • University of Virginia (US)
  • Breakthrough T1D (US)
  • Joslin Diabetes Center (US)
  • Endocrinology Research Center (RU)
  • KU Leuven (BE)
  • University of East Anglia (GB)
  • Schneider Children's Medical Center (IL)
  • Steno Diabetes Center Copenhagen (DK)
  • CGParkin Communications, Inc., Henderson, NV
  • Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
  • Biomedical Informatics Consultants LLC, Potomac, MD
  • DiaCare, Ahmedabad, Gujarat, India
  • University of Florida (US)
  • dQ&A Market Research, Inc., San Francisco, CA
  • Nihon University (JP)
  • Yale University (US)
  • Tel Aviv University (IL)
Corresponding author
Battelino, Tadej
Venue
Diabetes Care
Published
2019-06-08
Volume
42
Issue
8
Pages
1593-1603
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2948261890
Cited by
4,237
References
96
Citations by year
2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
FWCI
215.44
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion)
  • Pure Amsterdam UMC (acceptedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • Lirias (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Leona M. and Harry B. Helmsley Charitable Trust
  • University of Virginia
  • Insulet Corporation
  • MannKind Corporation
  • Dexcom
  • OPKO Health
  • Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
  • National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
  • Universiteit van Amsterdam
  • KU Leuven
  • Novo Nordisk
  • Roche Diabetes Care
  • National Institutes of Health (UL1TR001863)
  • U.S. Food and Drug Administration
  • Abbott Diabetes Care
  • National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
MeSH terms
Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.